IBC Ab002
Alternative Names: IBC-Ab002Latest Information Update: 29 Sep 2025
At a glance
- Originator ImmunoBrain Checkpoint
- Class Antidementias; Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
- Preclinical Amyotrophic lateral sclerosis; Frontotemporal dementia
- Research Neurodegenerative disorders
Most Recent Events
- 29 Sep 2025 IBC Ab002 is still in phase-I clinical trials in Alzheimer's disease (In adults, In the elderly) in Israel, Netherlands, United Kingdom (IV) (NCT05551741)
- 15 Aug 2023 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by ImmunoBrain Checkpoint
- 16 Jul 2023 Pharmacodynamics data from preclinical study in Alzheimer's disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)